Skip to content

Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices

Carotenoid Absorption and Metabolism From Green-leafy Vegetable Matrices - a Explorative Study in Short-bowel Patients and Healthy Controls - The Popeye-study

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02450227
Acronym
Popeye
Enrollment
22
Registered
2015-05-21
Start date
2015-01-31
Completion date
2015-12-31
Last updated
2016-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Ileostomy; Functional Disturbance

Brief summary

Absorption and metabolism of carotenoids from two types of spinach preparations will be investigated in two study groups, short bowel/ileostomy and healthy, respectively. The study will be conducted as a randomised, controlled, 2-way crossover study in 24 participants (12 in each group), randomized to two sequences (1-2, 2-1) of interventions with a more and a less bio-accessible spinach preparation. The serum, chylomicron and fecal/effluent levels of lutein and beta-carotene will be determined.

Detailed description

Absorption and metabolism of carotenoids from two types of spinach preparations will be investigated in two study groups, short bowel/ileostomy and healthy, respectively. The study will be conducted as a randomised, controlled, 2-way crossover study. Twenty four participants (12 in each group) will be randomized to two sequences (1-2, 2-1) of interventions with a more and a less bio-accessible spinach preparation (differentiates only on the basis of particle size). The intervention period is sub-divided into three parts: run-in period (48 hours) with a standardized low-carotenoid diet, 0-24 hours (follow-up period 1 (FP1)) and 24 hours - 2 weeks (FP2). The intervention periods will be separated by a wash-out period of at least 14 days. At start of each intervention, the intervention meal (breakfast) is served, followed by standardized, carotenoid-free meals in the following 24 hours. Participants will in FP1 and FP2 receive an intervention meal every second day. Participants will otherwise keep their habitual diets during these follow-up periods. Study participants are asked to collect urine during 24 hours before and after the first intervention meal in each period. They will also collect feces/ileostomy efflux for 24 hours before and after initiation of the intervention for short bowel/ileostomy patients and for 48 periods in the healthy volunteers, respectively. Overnight-fasting serum samples are drawn at day 1, 7 and 15 of each intervention period. On day 1 plasma samples are drawn at 0,1, 3, 4, 6, 7, 9 and 24 hours post first intervention meal. Plasma and effluent levels of lutein and beta-carotene will be determined and chylomicrons are also separated from these samples for determination of carotenoids. Volunteers also have their macula examined for density of the yellow spot before and after the intervention. Plasma and effluent levels of other carotenoids as well as fat-soluble vitamins are also determined. The samples will also be subjected to metabolic profiling for further exploration and hypothesis generation.

Interventions

DIETARY_SUPPLEMENTSpinach - Whole leaf (10 mg lutein)

Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

DIETARY_SUPPLEMENTSpinach - Minced (10 mg/lutein)

Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet

Sponsors

Agroscope Liebefeld-Posieux Research Station ALP
CollaboratorOTHER
Rigshospitalet, Denmark
CollaboratorOTHER
Herta Messerli Stiftung
CollaboratorUNKNOWN
Glostrup University Hospital, Copenhagen
CollaboratorOTHER
University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

List of inclusion criteria: * Healthy adults (18-80 years old) * Body Mass Index (BMI) between 18,9-28 * Normal fasting blood glucose (BS) (1,9-5,6 mmol/L) * Tolerates: Potatoes, rice, chicken, meat (non vegan/vegetarian). List of

Exclusion criteria

* Intestinal diseases (among healthy controls), systemic infections, psychiatric disorders, metabolic diseases (incl. diabetes), and any clinical condition/circumstance which assessed by the study official makes the person unfit for participation in the trial. * Patients diagnosed with short bowel syndrome (SBS). * Chronic or frequent use of medication. Primarily consumption of drugs with known effect/side effects on fat absorption. Further, anticoagulants (Marevan) and systemic treatment with glucocorticoids. * Have or have had a drug addiction * Smokers * Alcohol consumption beyond the recommended (7/14 units per week for women/men, respectively) * Intake of vitamins or other supplements (3 months before the study and during the study) (healthy controls). Subjects from the patient group included only with stable intake of dietary supplements through the last 3 months. * Sampling or donation of larger amount of blood e.g. as blood donors or to other scientific experiments from 3 months before the study until its completion. * allergy or intolerance to any of the foods included in the study. * Women who are nursing, pregnant or planning pregnancy * Not able to comply with the procedures protocol. * Macular degeneration to a degree greeter than or equal to a surface area with one or more drusen larger than 125 microns in diameter in at least one eye. * Cataracts, macular- or other ocular disease, preventing depiction of xanthophyll pigment. The following separate registered information was additionally recorded for short bowel/ileostomy patients: * Time since operation (stable, \>1 year post operation) * Type of disease/background for operation * Intestinal anatomy (inclusive length and type of residual intestine) * Type and doses of vitamin and other types of supplementation

Design outcomes

Primary

MeasureTime frameDescription
Serum concentration of lutein and beta-carotene15 daysDifference in serum concentration of lutein and beta-carotene between baseline and the end of each intervention period.

Secondary

MeasureTime frameDescription
Total lutein and beta-carotene sekretion with feces/ileostomy-efflux48/24 hoursTotal lutein and beta-carotene sekretion with feces/ileostomy-efflux 48 and 24 hours postprandial, for healthy and ileostomy patients, respectively.
Concentration of other carotenoids in the chylomicron/TLR fraction24 hoursChanges in concentration of other carotenoids in the chylomicron/TLR fraction (area under the curve, AUC) 24 hours post first intervention meal in each intervention periods.
Serum concentration of other carotenoids15 daysDifference in serum concentration of other carotenoids between baseline and the end of each intervention period.
Concentration of lutein and beta-carotene in the chylomicron/TLR fraction24 hoursChanges in concentration of lutein and beta-carotene in the chylomicron/TLR fraction (area under the curve, AUC) 24 hours post first intervention meal in each intervention periods.
Changes in metabolic markers24 hoursChanges in overall metabolic markers from urine 24 hours postprandial
Level of optical density of the macula luteaBaselineLevel of optical density in the macula lutea (MPOD), in the spectra where xanthophyll pigment is absorbing light.
Serum concentration of other fat-soluble vitamins15 daysDifference in serum concentration of other vitamins (A, E; D, K) between baseline and the end of each intervention period.

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026